Intel-powered comprehensive retina risk assessment software-as-a-service platform has been developed in India. Netra. AI analyzes images from portable.

‘Netra.AI analyzes images from portable, technician-operated fundus camera devices, for immediate results of referable diabetic retinopathy (DR) grading via a cloud-based web portal.’

"With Netra.AI, Sankara Eye Foundation and Leben Care have leveraged the power of Intel Xeon Scalable processors and built-in Intel Deep Learning (DL) Boost to accurately detect DR and enable timely treatment to effectively combat avoidable vision impairment and blindness in diabetic patients." Prakash Mallya, Vice President and Managing Director of Sales, Marketing and Communications Group, Intel India, said in a statement. 




Netra.AI analyzes images from portable, technician-operated fundus camera devices, for immediate results of referable DR grading via a cloud-based web portal.
The solution uses cutting-edge AI algorithms, developed in collaboration with leading retina experts, with a four-step deep convolutional neural network (DCNN).
So far, Netra.AI has screened 3,093 patients in India and identified 742 at-risk patients.
India has one of the largest diabetic populations of any country in the world, approaching 98 million cases by 2030.
Advertisement
Advertisement